Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

18.2%

84 terminated/withdrawn out of 461 trials

Success Rate

79.3%

-7.3% vs industry average

Late-Stage Pipeline

25%

116 trials in Phase 3/4

Results Transparency

72%

232 of 322 completed trials have results

Key Signals

14 recruiting232 with results73 terminated11 withdrawn

Enrollment Performance

Analytics

Phase 1

131(36.5%)

Phase 2

105(29.2%)

Phase 3

68(18.9%)

Phase 4

48(13.4%)

N/A

6(1.7%)

Early Phase 1

1(0.3%)

359Total

Phase 1(131)

Phase 2(105)

Phase 3(68)

Phase 4(48)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (461)

Showing 20 of 461 trials

NCT05376891Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

Role: collaborator

NCT07360314Phase 1Recruiting

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Role: collaborator

NCT07840287Phase 3Not Yet Recruiting

A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]

Role: collaborator

NCT06641908Phase 1Recruiting

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Role: collaborator

NCT03815643Phase 3Active Not Recruiting

Avelumab Program Rollover Study

Role: collaborator

NCT05396833Phase 1Completed

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Role: collaborator

NCT05882734Phase 1Completed

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Role: collaborator

NCT06433219Phase 2Completed

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Role: collaborator

NCT07355218Phase 3Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Role: collaborator

NCT07332481Phase 3Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Role: collaborator

NCT07499362Phase 2Recruiting

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Role: collaborator

NCT07166601Phase 1Recruiting

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Role: collaborator

NCT05650567Phase 2Terminated

Study of M5049 in DM and PM Participants (NEPTUNIA)

Role: collaborator

NCT07549412Phase 3Recruiting

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Role: collaborator

NCT06421935Phase 1Active Not Recruiting

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Role: collaborator

NCT07340827Phase 3Recruiting

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)

Role: collaborator

NCT03547973Phase 2Active Not Recruiting

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Role: collaborator

NCT03940703Phase 2Completed

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Role: collaborator

NCT05724602Phase 2Terminated

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT04170153Phase 1Active Not Recruiting

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Role: collaborator